
Join to view full profile
1144 Eastlake Ave E, Seattle WASeattle, WA 98109
Phone+1 855-557-0555
Dr. Menon is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2004 - 2007
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2002 - 2004
University of ConnecticutInternship, Internal Medicine, 2001 - 2002
Stanley Medical College SMCClass of 1999
Certifications & Licensure
ID State Medical License 2024 - 2029
WA State Medical License 2022 - 2027
AK State Medical License 2025 - 2027
WI State Medical License 2010 - 2023
MN State Medical License 2003 - 2012
TX State Medical License 2010 - 2012
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
- Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
- Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Publications & Presentations
PubMed
- Pre-treatment polyfunctionality percentage (PFA) of CD8+ T cells is associated with development of immune-related adverse events (irAEs) in patients receiving immune c...Jonathan Thompson, Katie Palen, Smitha Menon, Hui-Zi Chen, Tyce Kearl
Neoplasia. 2026-10-01 - QIM26-313: Improving Molecular Testing Rates in Advanced Thyroid Cancer Through a Standardized Testing Pathway.Lauren Shih, Perrin Romine, Mara Roth, Erik Konnick, Vera Paulson
Journal of the National Comprehensive Cancer Network. 2026-03-31 - QIM26-313: Improving Molecular Testing Rates in Advanced Thyroid Cancer Through a Standardized Testing Pathway.Lauren Shih, Perrin Romine, Mara Roth, Erik Konnick, Vera Paulson
Journal of the National Comprehensive Cancer Network. 2026-03-31
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: